CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D008881: Migraine Disorders NIH

(Synonyms: Mig, Migrai, Migrain, Migraine Diso, Migraine Disor, Migraine Disord, Migraine Disorders)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1762 Mindfulness program Wiki 0.58
drug2787 Symptomatic drugs Wiki 0.58
drug1763 Mindfulness session(s) Wiki 0.58
drug470 Bridge therapy Wiki 0.58
drug1756 Mindfulness Wiki 0.41

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D006261 Headache NIH 0.82
D051271 Headache Disorders, Secondary NIH 0.58
D004630 Emergencies NIH 0.10

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002076 Migraine HPO 1.00
HP:0002315 Headache HPO 0.82

There are 3 clinical trials

Clinical Trials


1 Mindfulness During COVID-19 - Remote Mindfulness Sessions

The objective of this study is to provide remote mindfulness session(s) to help during the COVID-19 pandemic.

NCT04319445 Migraine Disorders Stress Anxiety Behavioral: Mindfulness session(s)
MeSH:Migraine Disorders
HPO:Migraine

Primary Outcomes

Description: Total scale 1-5. Higher scores denotes better outcomes.

Measure: Helpfulness of the session

Time: Post-Intervention (upon completion of session up to 15 minutes)

Description: Total scale 1-5. Higher scores denotes better outcomes.

Measure: Platform effectiveness

Time: Post-Intervention (upon completion of session up to 15 minutes)

Secondary Outcomes

Description: Total scale 1-5. Higher scores denotes worse outcomes.

Measure: Change in Anxiety Level

Time: Pre- Intervention, Post-Intervention (upon completion of session up to 15 minutes)

Description: Total scale 1-5. Higher scores denotes worse outcomes.

Measure: Change in Stress Level

Time: Pre- Intervention, Post-Intervention (upon completion of session up to 15 minutes)

Description: Total scale 1-5. Higher scores denotes better outcomes.

Measure: Value of the session

Time: Post-Intervention (upon completion of session up to 15 minutes)

Description: Total scale 1-5. Higher scores denotes better outcomes.

Measure: Satisfaction with the session

Time: Post-Intervention (upon completion of session up to 15 minutes)

Measure: Percentage of participants that showed interest in a future session

Time: Post-Intervention (upon completion of session up to 15 minutes)

Measure: Percentage of participants that would recommend this session to a family member

Time: Post-Intervention (upon completion of session up to 15 minutes)

Description: Percentage of participants that would prefer to participate in daily, weekly or monthly similar sessions again if offered

Measure: Percentage of participants by session frequency preference

Time: Post-Intervention (upon completion of session up to 15 minutes)

Other Outcomes

Description: Total scale 1-5. Higher scores denotes worse outcomes.

Measure: Concern level about the COVID 19 pandemic

Time: Pre- Intervention, Post-Intervention (upon completion of session up to 15 minutes)

2 Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency

Chronic Migraine is a disabling condition that affects the 2% of migraine population. It is often associated with medication overuse that makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse but it is also confirmed that patients have to be carefully followed in the last period after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. It has been also reported how the clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. Generally patients after withdrawal follow a specific prophylaxis for migraine, but also come weekly to the hospital for practicing mindfulness for 6 sessionsAs the emergency situation due to the Corona-virus pandemic phenomenon in Italy, patients will miss the possibility to come for the regular practice to the hospital: for this reason the investigator propose a small pilot study to enforce the use of technology for our patients so that they can continue to be followed in their therapeutic process. This preliminary study will be conducted on 25 patients that have been submitted to a withdrawal according to the standard procedure at our hospital and they will practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at the hospital and also a weekly video-call to evaluate the clinical condition and to encourage to use strategies for pain management. This modality will allow the patients to continue their therapeutic process and to be followed regularly during the one year after withdrawal

NCT04389372 Migraine Headache Behavioral: Mindfulness
MeSH:Migraine Disorders Headache
HPO:Headache Migraine

Primary Outcomes

Description: Changes in migraine /days per month and medication intake/month (decrease of at least 50% in at least 50% of CM-MO patients)

Measure: Efficacy of Mindfullness by Smartphone

Time: at 6 months and 12 months follow-up compared with baseline (Headache Daily Diary)

Secondary Outcomes

Description: Changes in disability, impact Migraine Disability Assessment Score (MIDAS questionnaire) minimum score 0-maximum score 270 HIGHER SCORES worse outcome (they indicate more disability)

Measure: Change of Disability Score

Time: 6months - 12months

Description: Changes in Headache Impact Test (HIT-6) minimum score 36- maximum score 78 HIGHER SCORES worse outcome (they indicate more impact)

Measure: Change in Quality of life

Time: 6months - 12 months

3 Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up

Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse, but it is also confirmed that patients have to be carefully followed after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. Clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. As the emergency situation due to the Corona-virus pandemic phenomenon in Italy, the regular clinical practice adopted for patients with CM-MO has changed in the last weeks: patients cannot come to the hospital for the withdrawal iv therapy and for regular follow up as the reduced mobility due to the emergency in particular in the Lombardia region, but all over Italy. So the investigators propose a pilot study to enforce the application of a Home-program for the withdrawal procedure for patients and the use of technology like smartphone and video calls so that patients can continue to be followed in their therapeutic process by using behavioral support and mindfulness practice. Patients will perform the withdrawal program at home, by oral administration of therapies, with specific instructions and education. Also the information for behavioral approach and mindfulness practice will be given, to use every day at home. Daily standardized mindfulness sessions of 12 minutes on their smartphone will be combined with weekly video-call to evaluate the clinical condition and to encourage the use strategies for pain management. Face-to-face visits at the follow up every three months will be scheduled. This modality will allow the patients to continue their therapeutic process and to be regularly followed during the one year after withdrawal.

NCT04410536 Migraine, Hemicrania Drug: Symptomatic drugs Drug: Bridge therapy Behavioral: Mindfulness program
MeSH:Headache Disorders, Secondary Migraine Disorders Emergencies Headache
HPO:Headache Migraine

Primary Outcomes

Description: Drop-out rates after withdrawal treatment

Measure: Drop out rates

Time: at 12 months

Secondary Outcomes

Description: Percentages of patients with absence of Medication Overuse Headache

Measure: Absence of Medication Overuse Headache (MOH)

Time: at 12 months from withdrawal program (assessed by Daily Diary Card)


HPO Nodes